A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.